Characteristics of the 431 patients with AML per vitamin C/D supplementation
| . | Vitamin C/D supplementation . | P value . | Total . | |
|---|---|---|---|---|
| No . | Yes . | |||
| 262 (60.8%) . | 169 (39.2%) . | 431 (100.0) . | ||
| Age, y | ||||
| Median | 60.00 | 65.59 | .002 | 62.08 |
| IQR | 50.50-66.73 | 53.49-70.90 | 51.37-68.73 | |
| Min; max | 18.10; 78.81 | 19.13; 79.80 | 18.10; 79.80 | |
| Age (y), n (%) | .004 | |||
| ≤60 | 131 (50.0) | 61 (36.1) | 192 (44.5) | |
| >60 | 131 (50.0) | 108 (63.9) | 239 (55.5) | |
| Sex, n (%) | .399 | |||
| Male | 138 (52.7) | 82 (48.5) | 220 (51.0) | |
| Female | 124 (47.3) | 87 (51.5) | 211 (49.0) | |
| ECOG, n (%) | .011 | |||
| 0-1 | 179 (69.4) | 135 (80.4) | 314 (73.7) | |
| 2-3-4 | 79 (30.6) | 33 (19.6) | 112 (26.3) | |
| WBC (109/L) | ||||
| Median | 9.71 | 7.60 | 8.90 | |
| IQR | 2.90-46.06 | 2.50-33.50 | .152 | 2.70-41.30 |
| Min; max | 0.60; 403.30 | 0.42; 272.50 | 0.42; 403.30 | |
| WBC (109/L), n (%) | .387 | |||
| <50 | 200 (76.3) | 135 (79.9) | 335 (77.7) | |
| ≥50 | 62 (23.7) | 34 (20.1) | 96 (22.3) | |
| AML status n (%) | .545 | |||
| De novo | 199 (76.0) | 124 (73.4) | 323 (74.9) | |
| Secondary | 63 (24.0) | 45 (26.6) | 108 (25.1) | |
| Platelet count (109/L) | ||||
| Median | 64.00 | 63.00 | 64.00 | |
| IQR | 39.00-104.00 | 36.00-130.00 | .653 | 38.00-117.00 |
| Min; max | 5.00; 748.00 | 5.00; 848.00 | 5.00; 848.00 | |
| Creatinine μM/L (1N), n (%) | .003 | |||
| ≤84 μM/L | 147 (56.1) | 118 (70.2) | 265 (61.6) | |
| >84 μM/L | 115 (43.9) | 50 (29.8) | 165 (38.4) | |
| Albumin (g/L), n (%) | .783 | |||
| <30 | 50 (19.2) | 33 (20.2) | 83 (19.6) | |
| ≥30 | 211 (80.8) | 130 (79.8) | 341 (80.4) | |
| LDH (UI/L) (2N), n (%) | .346 | |||
| ≤468 UI/L | 149 (57.1) | 103 (61.7) | 252 (58.9) | |
| >468 UI/L | 112 (42.9) | 64 (38.3) | 176 (41.1) | |
| Serum ferritin (μg/L) (2N), n (%) | .531 | |||
| ≤613.6 μg/L | 126 (49.0) | 84 (52.2) | 210 (50.2) | |
| >613.6 μg/L | 131 (51.0) | 77 (47.8) | 208 (49.8) | |
| Corrected calcemia (mmol/L) | ||||
| Median | 2.34 | 2.33 | .741 | 2.33 |
| IQR | 2.25-2.44 | 2.26-2.40 | 2.25-2.43 | |
| Min; max | 1.96; 2.88 | 2.02; 2.81 | 1.96; 2.88 | |
| Cytogenetic risk, n (%) | .934 | |||
| Favorable | 27 (10.3) | 16 (9.6) | 43 (10.0) | |
| Intermediate | 177 (67.8) | 116 (69.5) | 293 (68.5) | |
| Adverse | 57 (21.8) | 35 (21.0) | 92 (21.5) | |
| ELN 2017, n (%) | .469 | |||
| Favorable | 92 (39.3) | 62 (37.8) | 154 (38.7) | |
| Intermediate | 75 (32.1) | 46 (28.0) | 121 (30.4) | |
| Adverse | 67 (28.6) | 56 (34.1) | 123 (30.9) | |
| FLT3-ITD mutation, n (%) | .130 | |||
| No | 141 (71.6) | 128 (78.5) | 269 (74.7) | |
| Yes | 56 (28.4) | 35 (21.5) | 91 (25.3) | |
| FLT3-TKD mutation, n (%) | .112 | |||
| No | 163 (91.6) | 144 (86.2) | 307 (89.0) | |
| Yes | 15 (8.4) | 23 (13.8) | 38 (11.0) | |
| NPM1 mutation, n (%) | .076 | |||
| No | 122 (57.5) | 111 (66.5) | 233 (61.5) | |
| Yes | 90 (42.5) | 56 (33.5) | 146 (38.5) | |
| CEBPA mutation, n (%) | .462 | |||
| No | 141 (93.4) | 144 (91.1) | 285 (92.2) | |
| Yes | 10 (6.6) | 14 (8.9) | 24 (7.8) | |
| Monoallelic | 6 (60.0) | 7 (50.0) | .696 | 13 (54.2) |
| Biallelic | 4 (40.0) | 7 (50.0) | 11 (45.8) | |
| IDH1-R132 mutation, n (%) | .181 | |||
| No | 206 (91.6) | 146 (87.4) | 352 (89.8) | |
| Yes | 19 (8.4) | 21 (12.6) | 40 (10.2) | |
| IDH2-R140 mutation, n (%) | .572 | |||
| No | 198 (88.0) | 150 (89.8) | 348 (88.8) | |
| Yes | 27 (12.0) | 17 (10.2) | 44 (11.2) | |
| IDH2-R172 mutation, n (%) | .060 | |||
| No | 222 (98.7) | 159 (95.2) | 381 (97.2) | |
| Yes | 3 (1.3) | 8 (4.8) | 11 (2.8) | |
| DNMT3A mutation, n (%) | .565 | |||
| No | 122 (75.8) | 131 (78.4) | 253 (77.1) | |
| Yes | 39 (24.2) | 36 (21.6) | 75 (22.9) | |
| TET2 mutation, n (%) | .653 | |||
| No | 39 (86.7) | 40 (83.3) | 79 (84.9) | |
| Yes | 6 (13.3) | 8 (16.7) | 14 (15.1) | |
| RUNX1 mutation, n (%) | .655 | |||
| No | 37 (86.0) | 43 (82.7) | 80 (84.2) | |
| Yes | 6 (14.0) | 9 (17.3) | 15 (15.8) | |
| ASXL1 mutation, n (%) | .361 | |||
| No | 49 (87.5) | 153 (91.6) | 202 (90.6) | |
| Yes | 7 (12.5) | 14 (8.4) | 21 (9.4) | |
| TP53 mutation, n (%) | .044 | |||
| No | 46 (97.9) | 58 (86.6) | 104 (91.2) | |
| Yes | 1 (2.1) | 9 (13.4) | 10 (8.8) | |
| At least 1 mutation in DNMT3A/TET2/ASXL1, n (%) | .354 | |||
| No | 22 (31.0) | 32 (38.1) | 54 (34.8) | |
| Yes | 49 (69.0) | 52 (61.9) | 101 (65.2) | |
| Chemotherapy regimen, n (%) | <.0001 | |||
| Daunorubicin-cytarabine | 58 (22.1) | 13 (7.7) | 71 (16.5) | |
| Idarubicin-cytarabine | 99 (37.8) | 78 (46.2) | 177 (41.1) | |
| Idarubicin-cytarabine-lomustine | 98 (37.4) | 59 (34.9) | 157 (36.4) | |
| Other | 7 (2.7) | 2 (1.2) | 9 (2.1) | |
| CPX-351 | 0 (0.0) | 17 (10.1) | 17 (3.9) | |
| Allogeneic SCT in CR1, n (%) | .112 | |||
| No | 146 (66.1) | 105 (73.9) | 251 (69.1) | |
| Yes | 75 (33.9) | 37 (26.1) | 112 (30.9) | |
| Median follow-up, mo (IQR) | 58.2 (50.5-67.0) | 28.7 (24.2-35.4) | <.0001 | 45.6 (29.8-61.5) |
| . | Vitamin C/D supplementation . | P value . | Total . | |
|---|---|---|---|---|
| No . | Yes . | |||
| 262 (60.8%) . | 169 (39.2%) . | 431 (100.0) . | ||
| Age, y | ||||
| Median | 60.00 | 65.59 | .002 | 62.08 |
| IQR | 50.50-66.73 | 53.49-70.90 | 51.37-68.73 | |
| Min; max | 18.10; 78.81 | 19.13; 79.80 | 18.10; 79.80 | |
| Age (y), n (%) | .004 | |||
| ≤60 | 131 (50.0) | 61 (36.1) | 192 (44.5) | |
| >60 | 131 (50.0) | 108 (63.9) | 239 (55.5) | |
| Sex, n (%) | .399 | |||
| Male | 138 (52.7) | 82 (48.5) | 220 (51.0) | |
| Female | 124 (47.3) | 87 (51.5) | 211 (49.0) | |
| ECOG, n (%) | .011 | |||
| 0-1 | 179 (69.4) | 135 (80.4) | 314 (73.7) | |
| 2-3-4 | 79 (30.6) | 33 (19.6) | 112 (26.3) | |
| WBC (109/L) | ||||
| Median | 9.71 | 7.60 | 8.90 | |
| IQR | 2.90-46.06 | 2.50-33.50 | .152 | 2.70-41.30 |
| Min; max | 0.60; 403.30 | 0.42; 272.50 | 0.42; 403.30 | |
| WBC (109/L), n (%) | .387 | |||
| <50 | 200 (76.3) | 135 (79.9) | 335 (77.7) | |
| ≥50 | 62 (23.7) | 34 (20.1) | 96 (22.3) | |
| AML status n (%) | .545 | |||
| De novo | 199 (76.0) | 124 (73.4) | 323 (74.9) | |
| Secondary | 63 (24.0) | 45 (26.6) | 108 (25.1) | |
| Platelet count (109/L) | ||||
| Median | 64.00 | 63.00 | 64.00 | |
| IQR | 39.00-104.00 | 36.00-130.00 | .653 | 38.00-117.00 |
| Min; max | 5.00; 748.00 | 5.00; 848.00 | 5.00; 848.00 | |
| Creatinine μM/L (1N), n (%) | .003 | |||
| ≤84 μM/L | 147 (56.1) | 118 (70.2) | 265 (61.6) | |
| >84 μM/L | 115 (43.9) | 50 (29.8) | 165 (38.4) | |
| Albumin (g/L), n (%) | .783 | |||
| <30 | 50 (19.2) | 33 (20.2) | 83 (19.6) | |
| ≥30 | 211 (80.8) | 130 (79.8) | 341 (80.4) | |
| LDH (UI/L) (2N), n (%) | .346 | |||
| ≤468 UI/L | 149 (57.1) | 103 (61.7) | 252 (58.9) | |
| >468 UI/L | 112 (42.9) | 64 (38.3) | 176 (41.1) | |
| Serum ferritin (μg/L) (2N), n (%) | .531 | |||
| ≤613.6 μg/L | 126 (49.0) | 84 (52.2) | 210 (50.2) | |
| >613.6 μg/L | 131 (51.0) | 77 (47.8) | 208 (49.8) | |
| Corrected calcemia (mmol/L) | ||||
| Median | 2.34 | 2.33 | .741 | 2.33 |
| IQR | 2.25-2.44 | 2.26-2.40 | 2.25-2.43 | |
| Min; max | 1.96; 2.88 | 2.02; 2.81 | 1.96; 2.88 | |
| Cytogenetic risk, n (%) | .934 | |||
| Favorable | 27 (10.3) | 16 (9.6) | 43 (10.0) | |
| Intermediate | 177 (67.8) | 116 (69.5) | 293 (68.5) | |
| Adverse | 57 (21.8) | 35 (21.0) | 92 (21.5) | |
| ELN 2017, n (%) | .469 | |||
| Favorable | 92 (39.3) | 62 (37.8) | 154 (38.7) | |
| Intermediate | 75 (32.1) | 46 (28.0) | 121 (30.4) | |
| Adverse | 67 (28.6) | 56 (34.1) | 123 (30.9) | |
| FLT3-ITD mutation, n (%) | .130 | |||
| No | 141 (71.6) | 128 (78.5) | 269 (74.7) | |
| Yes | 56 (28.4) | 35 (21.5) | 91 (25.3) | |
| FLT3-TKD mutation, n (%) | .112 | |||
| No | 163 (91.6) | 144 (86.2) | 307 (89.0) | |
| Yes | 15 (8.4) | 23 (13.8) | 38 (11.0) | |
| NPM1 mutation, n (%) | .076 | |||
| No | 122 (57.5) | 111 (66.5) | 233 (61.5) | |
| Yes | 90 (42.5) | 56 (33.5) | 146 (38.5) | |
| CEBPA mutation, n (%) | .462 | |||
| No | 141 (93.4) | 144 (91.1) | 285 (92.2) | |
| Yes | 10 (6.6) | 14 (8.9) | 24 (7.8) | |
| Monoallelic | 6 (60.0) | 7 (50.0) | .696 | 13 (54.2) |
| Biallelic | 4 (40.0) | 7 (50.0) | 11 (45.8) | |
| IDH1-R132 mutation, n (%) | .181 | |||
| No | 206 (91.6) | 146 (87.4) | 352 (89.8) | |
| Yes | 19 (8.4) | 21 (12.6) | 40 (10.2) | |
| IDH2-R140 mutation, n (%) | .572 | |||
| No | 198 (88.0) | 150 (89.8) | 348 (88.8) | |
| Yes | 27 (12.0) | 17 (10.2) | 44 (11.2) | |
| IDH2-R172 mutation, n (%) | .060 | |||
| No | 222 (98.7) | 159 (95.2) | 381 (97.2) | |
| Yes | 3 (1.3) | 8 (4.8) | 11 (2.8) | |
| DNMT3A mutation, n (%) | .565 | |||
| No | 122 (75.8) | 131 (78.4) | 253 (77.1) | |
| Yes | 39 (24.2) | 36 (21.6) | 75 (22.9) | |
| TET2 mutation, n (%) | .653 | |||
| No | 39 (86.7) | 40 (83.3) | 79 (84.9) | |
| Yes | 6 (13.3) | 8 (16.7) | 14 (15.1) | |
| RUNX1 mutation, n (%) | .655 | |||
| No | 37 (86.0) | 43 (82.7) | 80 (84.2) | |
| Yes | 6 (14.0) | 9 (17.3) | 15 (15.8) | |
| ASXL1 mutation, n (%) | .361 | |||
| No | 49 (87.5) | 153 (91.6) | 202 (90.6) | |
| Yes | 7 (12.5) | 14 (8.4) | 21 (9.4) | |
| TP53 mutation, n (%) | .044 | |||
| No | 46 (97.9) | 58 (86.6) | 104 (91.2) | |
| Yes | 1 (2.1) | 9 (13.4) | 10 (8.8) | |
| At least 1 mutation in DNMT3A/TET2/ASXL1, n (%) | .354 | |||
| No | 22 (31.0) | 32 (38.1) | 54 (34.8) | |
| Yes | 49 (69.0) | 52 (61.9) | 101 (65.2) | |
| Chemotherapy regimen, n (%) | <.0001 | |||
| Daunorubicin-cytarabine | 58 (22.1) | 13 (7.7) | 71 (16.5) | |
| Idarubicin-cytarabine | 99 (37.8) | 78 (46.2) | 177 (41.1) | |
| Idarubicin-cytarabine-lomustine | 98 (37.4) | 59 (34.9) | 157 (36.4) | |
| Other | 7 (2.7) | 2 (1.2) | 9 (2.1) | |
| CPX-351 | 0 (0.0) | 17 (10.1) | 17 (3.9) | |
| Allogeneic SCT in CR1, n (%) | .112 | |||
| No | 146 (66.1) | 105 (73.9) | 251 (69.1) | |
| Yes | 75 (33.9) | 37 (26.1) | 112 (30.9) | |
| Median follow-up, mo (IQR) | 58.2 (50.5-67.0) | 28.7 (24.2-35.4) | <.0001 | 45.6 (29.8-61.5) |
1N, upper limit of normal; 2N, 2 times the upper limit of normal; CR1, first CR; max, maximum; Min, minimum; SCT, stem cell transplantation; WBC, white blood cell count.